Cautious Optimism: Alnylam Pharma’s Strong TTR Franchise Growth and Hold Rating

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma yesterday and set a price target of $405.00.

Michael Ulz has given his Hold rating due to a combination of factors surrounding Alnylam Pharma’s recent performance and future prospects. The company has shown impressive growth in its TTR franchise, particularly with the strong launch of Amvuttra in the TTR-CM market, which has exceeded expectations. Despite this positive momentum and a significant increase in sales guidance, Ulz maintains a cautious stance.
While the sales figures are promising, Ulz suggests that the current valuation already reflects much of this success, and there might be limited additional upside in the near term. He notes that although the price target has been raised to $405, there are potentially more attractive investment opportunities elsewhere. This balanced view of recognizing the company’s achievements while considering broader market dynamics underpins his Hold recommendation.

According to TipRanks, Ulz is an analyst with an average return of -1.1% and a 40.82% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rhythm Pharmaceuticals, and Rocket Pharmaceuticals.

In another report released on July 17, Cantor Fitzgerald also maintained a Hold rating on the stock with a $290.00 price target.